Research Analysts Offer Predictions for Medexus Pharmaceuticals Inc.’s FY2025 Earnings (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Ventum Cap Mkts lowered their FY2025 EPS estimates for Medexus Pharmaceuticals in a report released on Monday, September 16th. Ventum Cap Mkts analyst S. Quenneville now expects that the company will post earnings per share of $0.24 for the year, down from their previous forecast of $0.26. Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at $0.05 EPS.

Medexus Pharmaceuticals (TSE:MDP) last released its quarterly earnings data on Wednesday, August 7th. The company reported C$0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.04 by C$0.07. The business had revenue of C$37.33 million during the quarter, compared to analysts’ expectations of C$36.95 million. Medexus Pharmaceuticals had a net margin of 1.00% and a return on equity of 3.95%.

Several other equities research analysts have also weighed in on MDP. Stifel Nicolaus raised their target price on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Stifel Canada upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$2.46 on Thursday. The business has a 50-day moving average of C$2.40 and a two-hundred day moving average of C$1.94. The company has a market capitalization of C$60.34 million, a price-to-earnings ratio of 49.20 and a beta of 1.95. Medexus Pharmaceuticals has a 1 year low of C$1.44 and a 1 year high of C$3.39.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.